CN113750119A - External preparation for treating diabetic foot and preparation process thereof - Google Patents
External preparation for treating diabetic foot and preparation process thereof Download PDFInfo
- Publication number
- CN113750119A CN113750119A CN202111181739.3A CN202111181739A CN113750119A CN 113750119 A CN113750119 A CN 113750119A CN 202111181739 A CN202111181739 A CN 202111181739A CN 113750119 A CN113750119 A CN 113750119A
- Authority
- CN
- China
- Prior art keywords
- external preparation
- extract
- skin
- water
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 49
- 208000008960 Diabetic foot Diseases 0.000 title claims abstract description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 35
- 241000251468 Actinopterygii Species 0.000 claims abstract description 26
- 210000003097 mucus Anatomy 0.000 claims abstract description 17
- 239000008213 purified water Substances 0.000 claims abstract description 14
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000004202 carbamide Substances 0.000 claims abstract description 8
- 150000002148 esters Chemical class 0.000 claims abstract description 7
- 239000004088 foaming agent Substances 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims abstract description 4
- 239000006260 foam Substances 0.000 claims description 28
- 235000019688 fish Nutrition 0.000 claims description 25
- 235000013336 milk Nutrition 0.000 claims description 22
- 239000008267 milk Substances 0.000 claims description 22
- 210000004080 milk Anatomy 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 22
- 239000011259 mixed solution Substances 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 8
- 230000010355 oscillation Effects 0.000 claims description 8
- 238000001179 sorption measurement Methods 0.000 claims description 8
- 239000004006 olive oil Substances 0.000 claims description 7
- 235000008390 olive oil Nutrition 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 241000195940 Bryophyta Species 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 235000011929 mousse Nutrition 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 241000205585 Aquilegia canadensis Species 0.000 claims description 4
- 241001071917 Lithospermum Species 0.000 claims description 4
- 238000003795 desorption Methods 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 229940119485 safflower extract Drugs 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 241000972773 Aulopiformes Species 0.000 claims description 3
- 241000276438 Gadus morhua Species 0.000 claims description 3
- 241001417495 Serranidae Species 0.000 claims description 3
- 241001125843 Trichiuridae Species 0.000 claims description 3
- 239000003240 coconut oil Substances 0.000 claims description 3
- 235000019864 coconut oil Nutrition 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 235000019515 salmon Nutrition 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 239000005639 Lauric acid Substances 0.000 claims description 2
- 241001622901 Scomberomorus commerson Species 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 241000630524 Taractes rubescens Species 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229960003964 deoxycholic acid Drugs 0.000 claims description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 2
- 239000007888 film coating Substances 0.000 claims description 2
- 238000009501 film coating Methods 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 238000002390 rotary evaporation Methods 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 2
- 241000555682 Forsythia x intermedia Species 0.000 claims 1
- 241001596950 Larimichthys crocea Species 0.000 claims 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 241000411851 herbal medicine Species 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 10
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 244000052616 bacterial pathogen Species 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000008338 local blood flow Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 description 22
- 239000000203 mixture Substances 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000006071 cream Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 244000020518 Carthamus tinctorius Species 0.000 description 3
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 241000555712 Forsythia Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010017711 Gangrene Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000011344 liquid material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010067633 Peripheral nerve lesion Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241001620072 Scomberomorus niphonius Species 0.000 description 1
- 241001274979 Selenotoca multifasciata Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical group 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to an external preparation for treating diabetic foot and a preparation process thereof. The external preparation is mainly prepared from the following raw materials: glycerol, a foaming agent, purified water, urea, a marine fish skin mucus extracting solution and ester substances. The external preparation can effectively prevent the infection of pathogenic bacteria of diabetic feet, maintain the wetness, is not easy to crack and improves the comprehensive function of local blood circulation of skin. The external preparation of the invention has the advantages of convenient use, low cost, more convenient carrying and relatively simple process, and is suitable for further industrialized mass production.
Description
Technical Field
The invention relates to the field of clinical disease prevention, in particular to foam milk for treating foot skin of a diabetic patient and a preparation method thereof.
Background
The diabetic foot is a general term for the pathological changes of foot pain, deep skin ulcer, acromelic gangrene and the like caused by diabetes comprehensive factors and is one of chronic complications of diabetes.
Foot ulcers are a manifestation of diabetes, mainly due to narrowing or obstruction of blood vessels in the lower limbs of patients, resulting in a significant reduction in blood supply to the foot, susceptibility to severe infections, and poor healing of wounds that eventually form ulcers, even requiring amputation in the critically ill. Since diabetic patients are also easy to suffer from peripheral nerve lesions, the protective sensation of feet is reduced or lost, and once inflammation, trauma and the like occur, the patients often cannot timely perceive the lesions, so that the lesions are enlarged and serious consequences are caused.
Therefore, foot protection for diabetics is very important. At present, no protective articles specially used for protecting the feet of the diabetic patients exist in the market.
Disclosure of Invention
In view of the defects of the prior art, the invention provides an external preparation for treating diabetic foot and a preparation process thereof. The external preparation is mainly prepared from the following raw materials: glycerol, a foaming agent, purified water, urea, a traditional Chinese medicine extracting solution, a marine fish skin mucus extracting solution and ester substances.
Specifically, the external preparation of the invention comprises the following components in percentage by volume and weight:
more preferably:
furthermore, the external preparation can also be added with traditional Chinese medicine extracting solution, and the traditional Chinese medicine extracting solution can be one or a combination of a safflower extracting solution, a forsythia extracting solution, a honeysuckle extracting solution and a lithospermum extracting solution.
Further, the marine fish skin mucus extractive solution is derived from marine fish, such as one of cod, grouper, salmon, tuna, Carnis Pseudosciaenae, hairtail, butterfish, Scomberomorus niphonius, and Duobao fish.
Further, the foaming agent is selected from one or more of coconut oil, amino acid, olive oil, sodium bicarbonate and sodium lauryl sulfate. Further, the foaming agent is selected from amino acids and coconut oil in volume ratio, and the amino acids: olive oil 2: 3.
Further, the ester is selected from one or more of phospholipid, lauric acid, myristic acid, triglyceride, lecithin, cholesterol, tween 80 and sodium deoxycholate. Further, the ester is selected from the group consisting of triglycerides and cholesterol, in weight ratios, triglyceride: cholesterol 1: 1.
Further, in order to improve the treatment effect of the diabetic foot, the extraction process of the traditional Chinese medicine extract disclosed by the invention comprises the following steps:
1) crude extraction: adding distilled water into the materials, oscillating in water bath at 45-5 deg.C for 20-40min at oscillation frequency of 80-150 rpm, extracting under oscillation, concentrating under reduced pressure in rotary evaporator to extract at 50-60 deg.C and pH of solvent of 8.5-9.5 for 3 times, and mixing filtrates;
2) fine extraction: adsorbing the filtrate obtained in the step 1) by using macroporous adsorption resin NKA at an adsorption flow rate of 5mL/min, desorbing by using 50% ethanol water solution at a desorption flow rate of 2BV/h, concentrating the refined extract, and standing at room temperature in a dark place.
Further, the extraction process of the traditional Chinese medicine extract comprises the following steps:
1) crude extraction: adding distilled water (liquid-material ratio of 20mL/g) into the Chinese medicinal materials, oscillating in water bath at 55 deg.C for 30min, maintaining oscillation frequency at 120 rpm, extracting under oscillation, concentrating under reduced pressure in rotary evaporator to obtain extract with temperature of 55 deg.C and pH of solvent of 9.0, extracting for 3 times, and mixing filtrates.
2) Fine extraction: fine extraction: adsorbing the filtrate obtained in the step 1) by using macroporous adsorption resin NKA at an adsorption flow rate of 5mL/min, desorbing by using 50% ethanol water solution at a desorption flow rate of 2BV/h, concentrating the refined extract, and standing at room temperature in a dark place for later use.
Further, the preparation process of the marine fish skin mucus extract comprises the following steps:
1) taking several sea fish strips, placing in purified water, adding 5% sodium chloride solution at water temperature below 20 deg.C, feeding for 2-3 days, filtering with purified water, removing clear water after filtering, and collecting filtrate;
2) dissecting the marine fish, taking the skin of the marine fish, placing the skin in a high-speed tissue triturator, crushing for 35-45 min at the rotating speed of 4000-4500 r/min to obtain homogenate, mixing with the filtrate obtained in the step 1), and stirring uniformly to obtain a mixed solution;
3) mixing the mixed solution obtained in the step 2) with purified water, concentrating to relative density of 1.1-1.15, adding 100% ethanol into the concentrated solution to make volume fraction reach 70%, rotary evaporating to dryness, collecting precipitate,
adding appropriate amount of purified water into the precipitate to obtain colloid, and obtaining extractive solution of mucus on skin of marine fish.
The preparation is an external preparation, and is preferably an external ointment, wherein the external ointment is one or more of ointment, cataplasm, a film coating agent, a liniment and foamed milk. The external ointment is foam milk.
The second purpose of the invention is to provide the components and the preparation process of the foam milk:
1) mixing the skin mucus of the marine fish with glycerol, water and urea, adding the traditional Chinese medicine extract and the ester substances, finally adding the mixed solution of the foaming agent, and stirring for 10-30min in a sterile environment at the temperature of 45-50 ℃;
2) placing the mixed solution into a mousse bottle for later use.
Compared with the prior art, pharmacological experiments and clinical experiments respectively prove that the external preparation has a treatment effect, and the treatment effect of the external preparation is shown in the treatment effects of the external preparation at 7 th, 10 th and 14 th days after treatment by taking a mouse as an example.
The external preparation of the invention has the advantages of convenient use, low cost, more convenient carrying and relatively simple process, and is suitable for further industrialized mass production.
Drawings
FIG. 1: changes before and after the diabetic foot after 1 day of treatment using the milk foam of example 5 of the present invention.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1: the extraction process of the traditional Chinese medicine extract comprises the following specific steps:
1) crude extraction: adding distilled water (liquid-material ratio of 20mL/g) into the Chinese medicinal materials, oscillating in water bath at 55 deg.C for 30min, maintaining oscillation frequency at 120 rpm, extracting under oscillation, concentrating under reduced pressure in rotary evaporator to obtain extract with temperature of 55 deg.C and pH of solvent of 9.0, extracting for 3 times, and mixing filtrates.
2) Fine extraction: fine extraction: adsorbing the filtrate obtained in the step 1) by using macroporous adsorption resin NKA at an adsorption flow rate of 5mL/min, desorbing by using 50% ethanol water solution at a desorption flow rate of 2BV/h, concentrating the refined extract, and standing at room temperature in a dark place for later use.
The traditional Chinese medicine raw material can be any one of safflower, forsythia, honeysuckle and lithospermum or more than two of the safflower, the forsythia, the honeysuckle and the lithospermum can be mixed and extracted.
Example 2: the preparation process of the marine fish skin mucus extract comprises the following steps:
1) 10kg of sea fish is taken and put in 1.5L of purified water, and 5% sodium chloride solution (water: feeding at 15-20 deg.C for 2-3 days with sodium hydroxide volume ratio of 1:0.15), filtering with purified water, removing the clear water, and collecting the filtrate;
2) dissecting the marine fish, taking the skin of the marine fish, placing the skin in a high-speed tissue triturator, crushing for 35-45 min at the rotating speed of 4000-4500 r/min to obtain homogenate, mixing with the filtrate obtained in the step 1), and stirring uniformly to obtain a mixed solution;
3) and (3) adding purified water into the mixed solution obtained in the step 2), mixing, concentrating to a relative density of 1.1-1.15, adding 100% ethanol into the concentrated solution to make the volume fraction reach 70%, performing rotary evaporation to dryness, collecting a precipitate, adding purified water (calculated by g/mL, the precipitate: water is 1:0.5), and colloid is prepared to obtain the marine fish skin mucus extract.
The sea fish skin mucus extractive solution is prepared from one or more of sea fish such as cod, grouper, salmon, tuna, Carnis Pseudosciaenae, hairtail, pomfret, Spanish mackerel, and Duobao fish by mixing and extracting. See the examples for details.
Example 3: a foam milk composition for foot skin of diabetic patients comprises the following components in percentage by volume:
the preparation method comprises the following steps:
1) mixing the cod skin mucus extract with glycerol, water and urea, adding glycerol and cholesterol, finally adding the mixed solution of amino acid and olive oil, and stirring for 10-30min in a sterile environment at the temperature of 45-50 ℃;
2) placing the mixed solution into a mousse bottle for later use.
Example 4: a foam milk composition for foot skin of diabetic patients comprises the following components in percentage by volume:
the preparation method comprises the following steps:
1) mixing the cod skin mucus extract with glycerol, water and urea, adding the safflower extract, the glycerol and the cholesterol, finally adding the mixed solution of amino acid and olive oil, and stirring for 10-30min in a sterile environment at the temperature of 45-50 ℃;
2) placing the mixed solution into a mousse bottle for later use.
Example 5: a foam milk composition for foot skin of diabetic patients comprises the following components in percentage by volume:
the preparation method comprises the following steps:
1) mixing the cod skin mucus extract with glycerol, water and urea, adding the safflower extract, the glycerol and the cholesterol, finally adding the mixed solution of amino acid and olive oil, and stirring for 10-30min in a sterile environment at the temperature of 45-50 ℃;
2) placing the mixed solution into a mousse bottle for later use.
Example 6: a foam milk composition for foot skin of diabetic patients comprises the following components in percentage by volume:
the preparation method is the same as example 3.
Example 7: a cream composition for foot skin of diabetic patients comprises the following components by volume ratio:
the preparation method of the cream comprises the following steps:
1) mixing the cod skin mucus extract with glycerol, water and urea, adding the safflower extract, the glycerol and the cholesterol, finally adding the mixed solution of amino acid and olive oil, and stirring for 10-30min in a sterile environment at the temperature of 45-50 ℃;
2) placing the mixed solution into a packaging bottle for later use.
Example 8: a foam milk composition for foot skin of diabetic patients comprises the following components in percentage by volume:
the preparation method is the same as example 3.
Comparative example 1: a foam milk composition for foot skin of diabetic patients comprises the following components in percentage by volume:
the preparation method is the same as example 3.
Comparative example 2: a foam milk composition for foot skin of diabetic patients comprises the following components in percentage by volume:
the preparation method is the same as example 3.
Comparative example 3: a foam milk composition for foot skin of diabetic patients comprises the following components in percentage by volume:
the preparation method is the same as example 3.
Comparative example 4: a foam milk composition for foot skin of diabetic patients comprises the following components in percentage by volume:
the preparation method is the same as example 3.
Verification examples
1) Antibacterial test of the pharmaceutical composition of the present invention
1.1 materials and methods
1) Strains and culture medium: sabouraud medium, Staphylococcus aureus, Candida albicans, Escherichia coli and Pseudomonas aeruginosa
The strains (all the strains are purchased from Beijing Beinanna Chuanglian union Biotechnology research institute).
2) Medicine preparation: the raw materials and the method of the invention in the embodiment 3-8 and the comparative example 1-4 are used to prepare the raw liquid of the medicine composition.
3) The method comprises the following steps: preparing Sabouraud medium, filling into conical flask, and sterilizing with damp heat. 1ml of each of the inventive examples 3 to 6, comparative examples 1 to 4 and 1: 20 of the sterilized physiological saline solution was aseptically dispensed into a sterilized dish, 10 dishes (10 cm in diameter) were prepared per dose, and the resulting mixture was poured into a flask of Sabouraud's culture to inoculate the above four kinds of bacteria (colonies having a diameter of about 0.5 mm). Incubate (37 ℃) for 6 days. The growth state of colonies and the presence or absence of growth of foreign bacteria were observed, and the diameter (mm) of the colonies was measured and compared with a blank group.
TABLE 1 antibacterial Effect of the respective example groups: (
n＝10)
Note: in contrast to comparative example 1,*P＜0.05，&P＜0.01；
in contrast to comparative example 4,#P＜0.05，@P＜0.01；
as can be seen from table 1 above, examples 3 to 6 of the present invention have significant antibacterial effects, and have significant inhibitory or killing effects on pathogenic bacteria such as staphylococcus aureus, candida albicans, escherichia coli, pseudomonas aeruginosa, and the like, and it can be seen that the antibacterial effects of examples 5 to 8 are superior to those of examples 3 to 4, while the antibacterial effects of examples 3 to 4 are superior to those of comparative examples 1 to 4.
2) Clinical trial and typical cases
(I) clinical efficacy observation of the traditional Chinese medicine composition for treating diabetic foot
1 data and method
1.1 general data
Patients with Diabetic Foot Ulcer (DFU) who were admitted to Shandong provincial Hospital from 1 month to 2021 month in 2019 were selected, 30 of them that met the clinical trial standards were selected as study subjects, and were randomly divided into an observation group and a control group by a random number table.
The observation group consisted of 10 cases, 5 men and 5 women; the age is 50-65 years, and the average age (55.44 +/-4.50) years; the course of diabetes is 5-10 years, and the average (7.11 +/-1.22) years; the disease course of DFU is 10-25 d, and the average (15.66 +/-7.14) d; ulcer area (5.77 +/-3.39) cm2(ii) a Wagner classification: stage I1, stage II 8, stage III 1 and stage IV 0.
Control 2 groups consisted of 10 cases, 5 men and 5 women; age 52-65 years, PingAll (55.58 + -3.21) years old; the course of diabetes is 5-11 years, and the average (7.22 +/-2.57) years; the disease course of DFU is 11-25 d, and the average (15.03 +/-3.91) d; ulcer area (6.28 +/-2.20) cm2(ii) a Wagner classification: stage I1, stage II 6, stage III 2 and stage IV 1.
By comparing the general data of the observation group and the treatment group, the difference between the two groups in terms of age, disease course, ulcer area and the like is not statistically significant (P > 0.05) and is not comparable.
1.2 diagnostic criteria and enrollment criteria
1.2.1 diagnostic criteria
The method comprises the following steps: and (3) Western diagnosis: refer to the Chinese guidelines for diagnosis and treatment of diabetic foot, which has a definite history of diabetes, and the feet have dry cracks, infection, ulcer or gangrene, and are confirmed to be DFU by auxiliary examination.
Secondly, the step of: the age is 50-65 years old, and the blood sugar is well controlled.
③: wagner grades I-IV, the area of the wound surface is less than or equal to 10cm2。
Fourthly, the method comprises the following steps: signing the informed consent.
1.2.2 exclusion criteria
Compliance with the "diagnostic criteria of 1.2.1" was included in the clinical trial. But the following (1) to (6) are to be excluded
(1) Combined genetic, infectious disease or malignancy; (2) obviously liver and kidney insufficiency or serious malnutrition; (3) severe infection is combined to cause systemic symptoms, the body temperature is more than 38 ℃, and the white blood cell count is more than 11 multiplied by 109Per liter; (4) pregnant or lactating women, (5) history of psychiatric illness; (6) the history of drug allergy.
1.3 methods
The patients of the observation group and the experimental group take the hypoglycemic drug to control the blood sugar level, improve the microcirculation, control the blood pressure, the blood fat level and other conditions. The control group and the observation group are treated by a conventional method, and the blood sugar of the patients is controlled and the wound infection is prevented.
The diabetic feet of the observation group are externally smeared with the foam milk of the invention example 5 for 3 times a day with the interval time of 8 hours, the dosage is evenly smeared, and the foam thickness is 1-2 cm.
The diabetic feet of the control group 1 were topically applied with the foam cream of comparative example 2 3 times a day at intervals of 8 hours, at a uniform application rate, and the foam thickness was 1-2 cm.
The control group 2 had diabetes mellitus sufficient the foam cream of this comparative example 4 was applied externally 3 times a day with an interval of 8 hours, and the amount was applied evenly with a foam thickness of 1-2 cm.
Both groups were evaluated for clinical treatment efficacy after 4 weeks of continuous treatment.
1.4 Observation index
All test items were performed before, 2 weeks and 4 weeks after treatment:
(1) the SK-III skin moisture detector measures the moisture content of the inner side of the forearm, 5 points are taken for measurement, the arithmetic mean value is taken, the testee uses the foam cream to evenly paint the foam cream on all feet until the foam cream is completely absorbed, the skin moisture tester is used for measuring the moisture content of the inner side of the forearm after 2 hours, 5 points are taken for measurement, and the arithmetic mean value is taken.
(2) Adverse reactions occurring during the course of treatment were recorded and observed.
1.5 therapeutic index
1.5.1 skin moisture content
The skin moisture content increase rate after 2 hours of using the milk foam was the average skin moisture after 2 hours of using the milk foam-the average skin moisture before using the milk foam.
1.5.2 treatment criteria for diabetic foot
And (3) curing: the degree of the dry skin crack of the foot is completely relieved, the moisture degree is more than 90%, and the increase of the average moisture of the skin is more than 5%.
The effect is shown: the degree of the dry skin of the foot is obviously relieved, the moisture degree is more than 80%, and the increase of the average moisture of the skin is 3-5%.
The method has the following advantages: the degree of the dry skin of the foot is effectively relieved, the moisture degree is more than 70%, and the increase of the average moisture of the skin is 0-3%.
And (4) invalidation: the dry cracking degree of the foot skin is not relieved, the wetness is below 70 percent, and the average moisture of the skin is not increased or even increased.
The total effective rate is the cure rate + the significant efficiency + the effective rate.
1.6 statistical methods
Statistical analysis using SPSS26.0 software for data measurement
The comparison among groups is shown by using independent sample t test, counting data is shown by percent, chi-square test is adopted, and P is less than 0.05, so that the difference has statistical significance.
2 results
2.1 Effect of the foam cream of the present invention on diabetic foot
Table 2 skin moisture test results table (
n＝10)
Note: in comparison with the control 1 group,*P＜0.05，#P＜0.01；
in comparison with the control 2 group,￥P＜0.05，△P＜0.01。
as can be seen from the above table 2, the foam cream in the embodiment 5 of the invention has a good moisturizing effect, can obviously improve the moisture content of skin after being used, and has the effects of moisturizing and moistening diabetes. Wherein the moisturizing effect of the observation group of example 5 was superior to that of the control groups 1-2.
TABLE 3 comparison of clinical efficacy of two groups of patients (example,%)
| Group of | Cure of disease | Show effect | Is effective | Invalidation | Total effective rate |
| Observation group | 2(20) | 7(70) | 1(10) | 0(0) | 100 |
| |
1(10) | 5(50) | 3(30) | 1(10) | 90 |
| Control 2 group | 0(0) | 6(60) | 2(20) | 2(20) | 80 |
As can be seen from Table 3 above, the milk foam of example 5 of the present invention has a very good therapeutic effect, and the therapeutic effect of the observation group of example 5 is superior to that of the control groups 1-2.
Claims (10)
1. The external preparation for treating diabetic foot is characterized by being prepared from the following raw materials:
2. the external preparation according to claim 1, which is prepared mainly from the following raw materials:
3. the external preparation of claim 1, wherein the external preparation further comprises one or more of a safflower extract, a forsythia extract, a honeysuckle extract, and a lithospermum extract.
4. The external preparation according to claim 1, wherein the extract of skin mucus of sea fish is derived from one or more of cod, grouper, salmon, tuna, yellow croaker, hairtail, pomfret, Spanish mackerel, and Duobao.
5. The external preparation as claimed in claim 1, wherein the foaming agent is selected from one or more of coconut oil, amino acid, olive oil, sodium bicarbonate, sodium lauryl sulfate.
6. The external preparation as claimed in claim 1, wherein the ester is selected from one or more of phospholipids, lauric acid, myristic acid, triglyceride, lecithin, cholesterol, tween 80 and sodium deoxycholate.
7. The external preparation of claim 1, wherein the extraction process of the Chinese herbal medicine extract comprises:
1) crude extraction: adding distilled water into the materials, oscillating in water bath at 45-5 deg.C for 20-40min at oscillation frequency of 80-150 rpm, extracting under oscillation, concentrating under reduced pressure in rotary evaporator to extract at 50-60 deg.C and pH of solvent of 8.5-9.5 for 3 times, and mixing filtrates;
2) fine extraction: adsorbing the filtrate obtained in the step 1) by using macroporous adsorption resin NKA at an adsorption flow rate of 5mL/min, desorbing by using 50% ethanol water solution at a desorption flow rate of 2BV/h, concentrating the refined extract, and standing at room temperature in a dark place.
8. The external preparation as claimed in claim 1, wherein the extraction process of the marine fish epidermal mucus extract is:
1) taking several sea fish strips, placing in purified water, adding 5% sodium chloride solution at water temperature below 20 deg.C, feeding for 2-3 days, filtering with purified water, removing clear water after filtering, and collecting filtrate;
2) dissecting the marine fish, taking the skin of the marine fish, placing the skin in a high-speed tissue triturator, crushing for 35-45 min at the rotating speed of 4000-4500 r/min to obtain homogenate, mixing with the filtrate obtained in the step 1), and stirring uniformly to obtain a mixed solution;
3) and (3) adding purified water into the mixed solution obtained in the step 2), mixing, concentrating to a relative density of 1.1-1.15, adding 100% ethanol into the concentrated solution until the volume fraction reaches 70%, performing rotary evaporation to dryness, collecting precipitate, adding a proper amount of purified water into the precipitate, and preparing colloid to obtain the marine fish skin mucus extract.
9. The external preparation according to any one of claims 1 to 8, wherein the external preparation is in a clinically acceptable dosage form; further, the external preparation is an external ointment; further, the external ointment is one or more of ointment, cataplasm, a film coating agent, a liniment and foamed milk; further, the external ointment is foam milk.
10. The preparation method of the external preparation of claim 9, wherein the foamed milk is prepared by the following steps:
1) mixing the skin mucus of the marine fish with glycerol, water and urea, adding an ester substance, finally adding a mixed solution of a foaming agent, and stirring for 10-30min in a sterile environment at the temperature of 45-50 ℃;
2) placing the mixed solution into a mousse bottle for later use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111181739.3A CN113750119A (en) | 2021-10-11 | 2021-10-11 | External preparation for treating diabetic foot and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111181739.3A CN113750119A (en) | 2021-10-11 | 2021-10-11 | External preparation for treating diabetic foot and preparation process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113750119A true CN113750119A (en) | 2021-12-07 |
Family
ID=78799106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111181739.3A Pending CN113750119A (en) | 2021-10-11 | 2021-10-11 | External preparation for treating diabetic foot and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113750119A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009149554A1 (en) * | 2008-06-11 | 2009-12-17 | National Research Council Of Canada | Antimicrobial components of the mucus and extruded slime of hagfish (myxine glutinosa) |
| CN102049037A (en) * | 2009-11-06 | 2011-05-11 | 李勇 | Application of ocean collagen peptide in process of preparing diabetes wound healing medicaments and foods |
| CN105560325A (en) * | 2015-12-31 | 2016-05-11 | 李秋 | Foamed emulsion for protecting skin of foot of diabetes patients and preparation method thereof |
| CN107670097A (en) * | 2017-10-19 | 2018-02-09 | 北京九鼎君健医药科技项城有限公司 | A kind of oligopeptide Wound dressing for promoting diabetes wound healing and preparation method thereof |
-
2021
- 2021-10-11 CN CN202111181739.3A patent/CN113750119A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009149554A1 (en) * | 2008-06-11 | 2009-12-17 | National Research Council Of Canada | Antimicrobial components of the mucus and extruded slime of hagfish (myxine glutinosa) |
| CN102049037A (en) * | 2009-11-06 | 2011-05-11 | 李勇 | Application of ocean collagen peptide in process of preparing diabetes wound healing medicaments and foods |
| CN105560325A (en) * | 2015-12-31 | 2016-05-11 | 李秋 | Foamed emulsion for protecting skin of foot of diabetes patients and preparation method thereof |
| CN107670097A (en) * | 2017-10-19 | 2018-02-09 | 北京九鼎君健医药科技项城有限公司 | A kind of oligopeptide Wound dressing for promoting diabetes wound healing and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 张箐鸿等: "胶原蛋白敷料与常规敷料治疗糖尿病足溃疡的比较" * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106692204B (en) | Probiotics composition for relieving or improving pelvic inflammation and preparation method thereof | |
| CN102091203A (en) | External traditional Chinese medicine preparation for treating chronic wounds and preparation method thereof | |
| CN1739741A (en) | Medicine for treating coronary heart disease and its prepn | |
| CN111759896A (en) | Pharmaceutical application of total triterpene of pawpaw | |
| CN115501246B (en) | Composition capable of effectively repairing, desalting and removing scars and preparation method and application thereof | |
| CN106620633A (en) | Skin repairing cream for tumor patients and preparation method of skin repairing cream | |
| CN113750119A (en) | External preparation for treating diabetic foot and preparation process thereof | |
| CN101332286B (en) | Traditional Chinese medicine composition for treating skin disease and preparation method thereof | |
| CN111557998A (en) | Traditional Chinese medicine composition for treating skin diseases and preparation method and application thereof | |
| CN104688769B (en) | Compound montmorillonite povidone iodine ointment and its preparation method and application | |
| WO2000078324A1 (en) | The leaves of cajanus cajan(l.) millsp and extract, formulation and uses thereof | |
| TW201309317A (en) | An extract of plant providing for treating the healing of wounds | |
| CN102485239A (en) | Chinese herbal composition used for treating gynecological inflammation | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| CN108815403A (en) | A kind of impaired five yellow liquor of bamboo Cape jasmine of the treatment skin histology of topical administration, purposes | |
| Krivoshchekov et al. | The results of complex treatment of patients after metatarsal resection concerning complications of diabetic foot syndrome | |
| CN109364148A (en) | A kind of FUKE QIANJIN PIAN and preparation method thereof | |
| CN114452354B (en) | Traditional Chinese medicine composition for wounds, extract and application thereof | |
| CN1194714C (en) | Chinese traditional medicine for treating psoriasis | |
| CN116036174B (en) | Medicine for treating pulmonary nodules and preparation method thereof | |
| CN115518111B (en) | Chinese herbal compound preparation for treating rhinitis and preparation method thereof | |
| CN107812147A (en) | A kind of pharmaceutical composition with anti-acne effect | |
| CN109674923A (en) | A kind of sterilizing soak composition and its preparation method and application | |
| CN115607592A (en) | Compound giant knotweed rhizome moist burn cream and preparation method thereof | |
| CN106344630B (en) | A kind of antiphlogistic and analgesic ointment and preparation method thereof containing chlorophyll |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211207 |